A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive ...

Current markers include plasma levels of chromogranin A, tumor metastases and Ki67 staining to determine the tumor proliferation rate ... to predict survival in patients with neuroendocrine ...

Survival (prognosis) for neuroendocrine cancer depends on many factors. These include your type and stage of neuroendocrine cancer. No one can tell you exactly how long you will live. Neuroendocrine ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine ... paired triplet misses survival mark in kidney cancer, Exelixis shifts ...

The approval was based on progression-free survival (PFS) and overall response rates (ORRs ... of Dana-Farber Cancer Institute, Boston, stated in a press release from Exelixis.